Optic Nerve Glioma

Optic Nerve Glioma is a type of tumor that grows on the optic nerve. These tumors usually develop in children. They can cause vision problems, like blurry vision or loss of vision in one eye.

Condition

What people with Optic Nerve Glioma report

Every report comes from a Lived member, sent anonymously.

Have you tried Carboplatin for Optic Nerve Glioma?

NameHow it went

About Optic Nerve Glioma

What It Is

An optic nerve glioma is a tumor that grows from the supporting (glial) cells of the optic nerve, the cable that carries signals from each eye to the brain. Because these tumors often spread along the connected visual pathway, including the optic chiasm where the two nerves cross, doctors usually call them optic pathway gliomas. Most occur in young children and are low-grade, meaning slow-growing tumors that rarely spread elsewhere in the body. The most common type is a pilocytic astrocytoma. Even so, they matter because of where they sit: as a tumor presses on or grows within the nerve, it can gradually reduce vision in one or both eyes. Tumors that reach the hypothalamus, a nearby brain area that controls hormones, can also affect growth and puberty. In adults the tumor is rare and is often a very different, more aggressive disease.

Causes & Risk Factors

The strongest known risk factor is neurofibromatosis type 1 (NF1), an inherited condition that causes skin changes such as café-au-lait spots and a tendency to grow tumors along nerves. About one in five people with NF1 develops an optic pathway glioma, usually before age 7. In children with NF1 the tumor tends to stay within the optic nerves and chiasm, and many never cause symptoms. Tumors in children without NF1 (often called sporadic) have no identified cause. They are more likely to involve the chiasm and the pathway behind it, and more likely to affect vision and hormones. Because of the NF1 link, anyone diagnosed with an optic pathway glioma is usually checked for NF1, and children with NF1 have regular eye examinations.

How It's Diagnosed

In a young child, the first signs are often noticed by parents or an eye doctor rather than reported by the child: poor vision, an eye that turns in or out, a bulging eye, or new wobbling or shimmering eye movements (nystagmus). Vision can decline so gradually over months that it is easy to miss. Some tumors, especially in NF1, are found on an MRI done for another reason. Magnetic resonance imaging (MRI) of the brain and eye sockets is the key test, showing the size and extent of the tumor. An eye specialist measures how sharply each eye sees, the side vision (visual field), color vision and how the pupils react, and looks at the optic nerve at the back of the eye. Many centers also use optical coherence tomography (OCT), a quick light scan that measures the thickness of the nerve fiber layer in the retina; thinning suggests nerve damage, which is useful in children too young for reliable vision tests. A biopsy is usually not needed and is generally avoided, because taking tissue from the nerve can itself damage vision. When the imaging pattern is typical, doctors diagnose the tumor from the MRI, the eye findings and the history. A biopsy is considered mainly when the picture is unusual or a higher-grade tumor is suspected.

Treatment Options

Many optic pathway gliomas, particularly in children with NF1, are watched rather than treated. Observation means eye exams and MRI scans every few months at first, because some tumors stay stable for years and a few even shrink on their own. The trigger for treatment is usually vision getting worse, or vision already damaged and at clear risk, not growth on a scan alone. Treatment aims to protect remaining vision; it rarely restores sight that has already been lost. When treatment is needed, chemotherapy is the usual first step, most often carboplatin and vincristine given through a vein over many months, or vinblastine alone in some centers. It controls the tumor in many children, though roughly half eventually need another treatment later. Targeted medicines have widened the options. Many of these tumors carry a change in a gene called BRAF that switches on a growth signal inside the cells, and the drugs block steps in that signal (BRAF itself, or a later step called MEK). For tumors with one specific BRAF change (V600E), the combination of dabrafenib and trametinib (Tafinlar and Mekinist), taken by mouth, is approved for children 1 year and older. Tovorafenib (Ojemda) is approved for tumors with a BRAF change that come back or stop responding to earlier treatment; it is not used for NF1 tumors without a BRAF change, because it may make them grow. Other drugs that block MEK, such as selumetinib, are being studied for these tumors. These pills avoid some chemotherapy side effects but bring their own, such as skin and muscle-enzyme changes, and need regular monitoring. Radiation can control the tumor but is generally avoided in young children, because it can affect brain development and hormones, and in people with NF1, who have a higher risk of radiation-related second cancers. Surgery is used only in selected situations, such as a single affected eye that is already blind and bulging, or a tumor causing pressure or fluid buildup in the brain, because removing the whole tumor usually is not possible without harming vision. Adults are a separate situation. Because adult optic gliomas are often high-grade, determining the grade, sometimes with a biopsy, guides a plan that differs from the childhood approach.

What to Expect

For children, the outlook for survival is generally good: more than 90 percent are alive 10 years after diagnosis. The bigger concern is long-term effects. The course is unpredictable, and the tumor may stay stable, grow slowly or grow in spurts, so follow-up continues for many years, with closer checks in early childhood. Tumors diagnosed in children with NF1 usually behave more mildly than those in children without it. Many survivors live with some lasting vision loss, ranging from reduced sharpness or side vision in one eye to severe loss in both. Vision services, low-vision aids and school accommodations can make a meaningful difference to learning and independence. Children whose tumor involves the hypothalamus, or who had radiation, need regular checks of growth, puberty and hormone levels, since hormone deficiencies are common and treatable with replacement. Some children also have learning or attention difficulties, especially those with NF1, so developmental and school support is often part of care. In adults, optic gliomas are rare. About half of reported adult cases are high-grade tumors, which can cause rapid vision loss and carry a much more serious outlook than the childhood form.

When to Seek Help

Arrange an eye examination for a child who does not seem to see well, holds objects very close, has an eye that turns or bulges, or develops new wobbling eye movements. Signs of puberty starting unusually early, or growth slowing, are also worth raising with a doctor. Children with NF1 should keep up their scheduled eye checks even when they seem to see normally. If your child is known to have an optic pathway glioma, contact the care team promptly about any noticeable change in vision, a newly bulging eye, or headaches that are worst in the morning or come with vomiting or unusual sleepiness, which can signal pressure building in the brain.

Questions to Ask Your Doctor

  1. 1.Is this tumor related to NF1, and how does that change how closely we watch it and which treatments make sense?
  2. 2.What will tell us it is time to start treatment, and how will we track vision at my child's age?
  3. 3.If treatment is needed, how do chemotherapy and targeted medicines compare for this tumor, and should it be tested for a BRAF change?
  4. 4.Does the tumor involve the hypothalamus, and what hormone or growth checks will be needed?
  5. 5.What vision, school or developmental support should we arrange now?

Last reviewed • Oct 2026

Educational content, not medical advice.